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Background: Effects of fish oil on systematic inflammation in chronic heart failure remain unclear. In this
meta-analysis, we aimed to evaluate the influence of fish oil supplementation on circulating levels of inflammatory
markers in patients with chronic heart failure.
Methods: Human randomized controlled trials, which compared the effects of fish oil supplementation with
placebo in patients with chronic heart failure, were identified by systematic search of Medline, Embase, Cochrane’s
library and references cited in related reviews and studies up to November 2011. Outcome measures comprised the
changes of circulating inflammatory markers. Meta-analysis was performed with the fixed-effect model or
random-effect model according to the heterogeneity.
Results: A total of seven trials with eight study arms were included. The pooled results indicated circulating levels
of tumor necrosis factor α (SMD = -0.62, 95% CI -1.08 to -0.16, p = 0.009), interleukin 1 (SMD = -1.24, 95% CI -1.56 to
-0.91, p < 0.001) and interleukin 6 (SMD = -0.81, 95% CI -1.48 to -0.14, p = 0.02) were significantly decreased after
fish oil supplementation; however, high sensitivity C reactive protein, soluble intracellular adhesion molecular 1 and
vascular cell adhesion molecular 1 were not significantly affected. Meta-regression and subgroup analysis results
suggested the difference in dose of fish oil and follow-up duration might influence the effects of fish oil on tumor
necrosis factor α and interleukin 6. Greater reduction of these two markers might be achieved in patients taking fish
oil of a higher dose (over 1000 mg/day) or for a longer duration (over 4 months).
Conclusions: Limited evidence suggests anti-inflammation may be a potential mechanism underlying the
beneficial effects of fish oil for chronic heart failure. Further large-scale and adequately powered clinical trials are
needed to confirm these effects.
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Chronic heart failure (CHF) is a common clinical syn-
drome which can be caused by various cardiovascular
disorders [1-3]. Despite recent advances in therapeutic
strategies, CHF is still one of the leading causes of mor-
bidity and mortality worldwide [4,5]. Although current
treatments improve clinical symptoms and slow progres-
sion of cardiac dysfunction, the prognoses for patients* Correspondence: lixy301@163.com
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reproduction in any medium, provided the orwith CHF remain poor [5,6]. Therefore, there is an
urgent need for development of novel therapy for CHF.
Fish oil, mainly consisting of two categories of marine
omega 3 polyunsaturated fatty acids (PUFAs) - eicosa-
pentaenoic acid (EPA) and ducosahexanoic acid (DHA),
has been suggested to be a potential adjunctive therapy
for many cardiovascular disorders, including CHF [7,8].
A recent clinical trial [9] showed a statistically significant
improved mortality or cardiovascular hospitalizations
(-8%; p < 0.01) in patients with CHF who received add-
itional fish oil supplementation. However, the exact
mechanisms underlying benefits of fish oil to patients
with CHF are not fully understood. Inflammation plays. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CHF [10,11]. Levels of circulating inflammatory markers,
including high sensitivity C reactive protein (hsCRP),
tumor necrosis factor α (TNF-α), interleukin 1 (IL-1),
interleukin 6 (IL-6), soluble intracellular adhesion
molecule-1 (sICAM-1) and soluble vascular cell adhe-
sion molecule-1 (sVCAM-1) et al., were elevated in
patients with CHF, serving as prognostic markers or
therapeutic targets [11-14]. Fish oil has been suggested
to exert anti-inflammation effects in patients with CHF
[7,8,15]. However, clinical trials in humans have shown
inconsistent results [16-23]. Herein, we aimed to evalu-
ate the effects of fish oil on levels of the above inflam-
matory markers in CHF through meta-analysis of
randomized, placebo-controlled clinical trials.
Methods
Search strategy
We systematically searched Pubmed (from 1950 to
November, 2011), Embase (from 1966 to November,
2011) and the Cochrane Library (Cochrane Center
Register of Controlled Trials) for relevant records, using
the term “omega-3 fatty acids”, “fish oil”, “fish-oil”, “mar-
ine oil”, “eicosapentaenoic acid”, “EPA”, “docosahexae-
noic acid”, “DHA”, “dietary therapy” paired with the
following: “heart failure”, “cardiac failure”, “cardiac dys-
function”, “ventricular dysfunction”, “ventricular insuffi-
ciency”, and “cardiomyopathy”. The search was limited
to studies in human. We also analyzed reference lists of
original and review articles using a manual approach.
Study selection
Studies were selected for analysis if they met the follow-
ing criteria: 1) published as full-length articles in any
language; 2) reported as a prospective, randomized, and
placebo-controlled trial with either a parallel or a cross-
over design (regardless of sample size); 3) analyzed adult
patients with established CHF (regardless of the etiology
and severity of the disease) who were assigned to oral
fish oil supplementation or placebo for at least one
month in addition to concurrent therapy; 4) reported
data on levels of at least one of the following circulating
inflammatory factors, including hsCRP, TNF-α, IL-6,
IL-1, sICAM-1 or sVCAM-1.
Data extraction and quality assessment
Searching, data extraction, and quality assessment were
completed independently by two authors (WX and WW)
according to inclusion criteria. Discrepancies were
resolved by consensus. Extracted data included study
design characteristics, patient characteristics (number,
age, sex, cardiac function, baseline circulating levels of in-
flammatory markers, and concurrent medications), inter-
vention strategies (dose of EPA and DHA, ratio of EPA toDHA and composition of placebo), follow-up duration,
and means and standard deviations (SDs) for changes of
the aforementioned inflammatory markers from baseline.
If the study provided medians and interquartile ranges
(IQRs) instead of means and SDs, we imputed the means
and SDs as described previously [24]. For studies with
multiple intervention groups (e.g. with different doses of
fish oil), we split the shared control group into two or
more groups with smaller sample size to overcoming a
unit-of-analysis error, and included these two or more
comparisons into the meta-analysis according to the in-
struction of Cochrane’s Handbook [25].
The quality of the studies was judged by quality of
randomization, generation of random numbers, conceal-
ment of treatment allocation, blinding, and reporting of
withdrawals. Trials scored one point for each area
addressed, with a possible score between 0 and 5, where
5 represented the highest level of quality [26].
Statistical analysis
All endpoints were estimated based on the change from
baseline to follow-up, and pooled effects were presented
as standardized mean difference (SMD) with 95% confi-
dence intervals (CI) because various measurements were
applied in the included studies. Inter-study heterogeneity
was formally tested using Cochrane’s Q test, and signifi-
cant heterogeneity was considered existing if p value was
< 0.10. The I2 statistic was also examined, and a value of
I2 > 50% indicated significant heterogeneity among the
trials [27]. If above tests showed no significance of het-
erogeneity among the included trials, fixed-effect model
was used to calculate SMD and its 95% CI. By contrast,
if there is significant heterogeneity among the included
studies, random-effect model was applied [28]. Meta-
regression analysis and predefined subgroup analysis was
performed to explore the possible source of heterogen-
eity. Furthermore, potential publication bias was
assessed with Egger regression asymmetry test [29] and
funnel plots; p values were two-tailed and statistical sig-
nificance was set at 0.05. Meta-analysis and statistical
analysis was performed with Stata software (version 12.0;
Stata Corporation, College Station, TX) and RevMan




A total of 1250 records were identified, and 1210 were
excluded because they did not describe randomization
or controlling, or because the objectives of these studies
were irrelevant to the present meta-analysis. Of the 40
potentially relevant records screened, eight met the se-
lection criteria for the current meta-analysis [16-23]
(Figure 1). Thirty-two records were excluded because
Figure 1 Flow diagram of the study selection procedure.
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5 trials didn’t report any data of related outcomes; 1 trial
included children with CHF and 1 trial reported incom-
plete data of related outcomes.
Study characteristics
Two of the included records reported the outcomes of
different inflammatory markers from the same study
population (one record of hsCRP [21], the other of
TNF-α and IL-6 [22]), which makes a total of 7 trials
included. This trial by Moertl et al. [21,22] included two
intervention groups of different doses of fish oil (a
higher dose group of 3360 mg/d and a lower dose group
of 840 mg/d), which we included in our study separately.
Overall, a total of 8 study arms from 7 trials were
included in this meta-analysis (Table 1 and Table 2), of
which 6 had a parallel design [16,18-23] and 1 had a
crossover design [17].
All of the studies declared that the participants were
clinically and hemodynamically stable CHF patients who
received optimal medical therapy based on modern CHF
treatment strategies, including diuretics and neurohor-
monal inhibitors, and the medication treatment was
maintained during the follow-up interval. Statins were
also taken by 83%, 54% and 14% of the participants in
three of the studies [17,20,23], not taken in one study
[16], and not reported in the rest three studies
[18,19,21,22]. The mean age of the participants of the
included studies varied from 57 to 73. The etiology of
CHF is exclusively ischemic in 1 trial [17], non-ischemic
in 3 trials [18,21-23], and from both in 3 trials[16,19,20]. Only one study reported inclusion of the
CHF patients primarily caused by myocarditis (5 of the
43 included participants) [22]. However, patients with
acute myocarditis were excluded from this study. The
baseline cardiac functions were of classes I – IV defined
by New York Heart Association (NYHA) and the base-
line left ventricular ejection fraction (LVEF) of the parti-
cipants varied from 17% to 36%. The dosage of fish oil
(calculated as total dose of EPA and DHA) ranged from
600 mg/day to 5440 mg/day, with the ratio of EPA to
DHA varying from 0.38 to 1.83. The duration of the in-
vestigation varied from 3 months to 12 months.
Data quality
The quality score of the 7 trials ranged form 3 to 5. All
of the included trials were randomized and placebo-
controlled, with 6 studies in a double-blind fashion
[16-18,20-23] and 1 in a single-blind fashion [19]. Two
of the trials reported methods of random sequence gen-
eration [19,21,22], while only one study reported alloca-
tion concealment [21,22]. Details of withdrawals were
reported in all of the 7 included trials.
Effects of fish oil supplementation on hsCRP in CHF
Four trials [17,19-21] including 5 study arms investigated
the effects of fish oil supplementation on hsCRP levels in
CHF patients (Table 2), but none of these studies showed
a significant effect. No significant heterogeneity was
found between the 5 study arms (I2 = 0.0%, p = 0.954),
therefore the fixed-effect model was applied. The pooled
results indicated that additional supplementation of fish
oil didn’t significantly reduced the circulating level of
hsCRP (SMD = -0.02, 95% CI -0.26 to 0.21, p = 0.84;
Figure 2) in patients with CHF. Sensitivity analysis, ex-
cluding the two study arms in which hsCRP data were
imputed from median and IQRs [21], also suggested an
insignificant effect (SMD = -0.02, 95% CI -0.27 to 0.23,
p = 0.87).
Effects of fish oil supplementation on TNF-α
Six trials [16-19,22,23] including 7 study arms reported
the effects of fish oil supplementation on TNF-α in CHF
(Table 2). Significant heterogeneity was found among
these 7 study arms (I2 =72.0%, p = 0.002). The pooled
analysis of the overall effect suggested that fish oil signifi-
cantly reduced the level of circulating TNF-α (SMD =
-0.62, 95% CI -1.08 to -0.16, p = 0.009; Figure 3A) in
patients with CHF. Sensitivity analysis, excluding the two
study arms in which TNF-α data were imputed from
median and IQRs [22], didn’t affect the result (SMD =
-0.77, 95% CI -1.32 to -0.22, p = 0.006).
In view of the fact that statistical heterogeneity existed
across the enrolled study arms, we performed meta-
regression analysis including some predefined covariates

























y % % % % % % mg/d mg/d mg/d months
Mehra
2006
14 60 71 43 III-IV 17 93 64 0 5440 3520 1920 1.83 4 Corn oil R, DB, PC 3
O'Keefe
2006







44 63 91 0 II-III 36.2 100 100 NR 1440 540 900 0.60 6 Olive oil R, DB, PC 3
Zhao
2009
75 73 73 64 II-III 31 100 87 NR 600 360 240 1.50 3 NR R, SB, PC 3
Eschen
2010
138 60 86 68 II-III 32 95 88 54 900 490 410 1.20 6 Olive oil R, DB, PC 3
Moertl
2011 a
22 57 83 0 III-IV 24.3 100 100 NR 840 465 375 1.24 3 Gelatin R, DB, PC 5
Moertl
2011 b
21 60 94 0 III-IV 24.2 100 100 NR 3360 1860 1500 1.24 3 Gelatin R, DB, PC 5
Nodari
2011
133 63 75 0 I-II 36.5 100 100 14 1950 730 1220 0.60 12 Olive oil R, DB, PC 3
The study by Moertl et al. includes two intervention groups of different dosages of EPA + DHA (Moertl 2011a, EPA + DHA 840 mg/day and Moertl 2011b, EPA + DHA 3360 mg/day).
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; EPA, eicosapentaenoic acid; DHA, ducosahexenoic acid; R,



















Table 2 Mean baseline circulating levels of the
inflammatory markers
Study hsCRP TNF-α IL-1 IL-6 sICAM-1 sVCAM-1
μg/ml pg/ml pg/ml pg/ml pg/ml pg/ml
Mehra 2006 NR 1.5 NR NR NR NR
O'Keefe 2006 1.3 6.7 NR 1.6 NR NR
Nodari 2009 NR 19.0 402.0 7.15 NR NR
Zhao 2009 5.6 61.5 NR 11.3 1.0 1.6
Eschen 2010 2.1 NR NR NR 0.3 0.7
Moertl 2011 a 5.0 2.5 NR 3.7 NR NR
Moertl 2011 b 5.0 2.3 NR 3.2 NR NR
Nodari 2011 NR 23.0 483.0 10.6 NR NR
The study by Moertl et al. includes two intervention groups of different
dosages of EPA + DHA (Moertl 2011a, EPA + DHA 840 mg/day and Moertl
2011b, EPA + DHA 3360 mg/day).
hsCRP, high sensitivity C reactive protein; TNF-α, tumor necrosis factor α; IL-1,
interleukin 1; IL-6, interleukin 6; sICAM-1, soluble intracellular adhesion
molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; NR, not
reported.
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results indicated that follow-up duration was negatively
related to effect size (regression coefficient = -0.12, 95%
CI -0.19 to -0.05, p = 0.009), which largely explained the
heterogeneity of the effect (Figure 3A). The mean age,
gender of the participants, etiology of CHF, baseline
LVEF, baseline TNF-α, doses of EPA or DHA, total dose
of fish oil and the ratio of EPA to DHA were not signifi-
cant modifiers to the effects of fish oil supplementation
on TNF-α.
Additionally, we conducted a predefined subgroup
analysis to observe the influence of study characteristics
to the effects of fish oil supplementation on TNF-α
(Table 3). The results showed that the differences in
total dose of fish oil and the follow-up duration might
influence the effects of fish oil on TNF-α significantly.
Specifically, fish oil supplementation with total dose overFigure 2 Forest plot from meta-analysis of standardized mean differe
with CHF randomized to fish oil or placebo. The effect size of each stud
overall summary estimate for the analysis; the width of the diamond repres
reactive protein; SMD, standardized mean difference; CI, confidence interva1000 mg/day or for duration over 4 months seemed to
associate with a more remarkable reduction of TNF-α.
Effects of fish oil supplementation on IL-1
Only two trials [18,23] reported the effects of fish oil
supplementation on IL-1 in CHF (Table 2), between
which no significant heterogeneity was found (I2 =46.0%,
p =0.173). The pooled results indicated that fish oil
reduced the level of circulating IL-1 (SMD = -1.24, 95%
CI -1.56 to -0.91, p < 0.001; Figure 3B) in patients with
CHF.
Effects of fish oil supplementation on IL-6
Five trials [17-19,22,23] including 6 study arms reported
the effects of fish oil on IL-6 in CHF (Table 2). Signifi-
cant heterogeneity was found among these study arms
(I2 = 85.8%, p < 0.001). The pooled results indicated that
fish oil significantly reduced the level of circulating IL-6
(SMD = -0.81, 95% CI -1.48 to -0.14, p = 0.02;
Figure 3C) in patients with CHF. However, sensitivity
analysis, excluding the two study arms in which IL-6
data were imputed from median and IQRs [22], sug-
gested an insignificant effect of fish oil on IL-6 (SMD =
-0.81, 95% CI -1.72 to 0.10, p = 0.08).
The results of meta-regression analysis include some
predefined covariates indicated that follow-up duration
was negatively related to effect size (regression coeffi-
cient = -0.016, 95% CI -0.004 to -0.028, p = 0.017),
which may partially explain the heterogeneity of the ef-
fect (Figure 3C).
Subgroup analysis showed that the differences in total
dose of fish oil and the follow-up duration might influ-
ence the effects of fish oil on IL-6. Specifically, fish oil
supplementation with a dose over 1000 mg/day or for
duration over 4 months seemed to relate to a greater re-
duction of circulating IL-6 (Table 3).nce in circulating high sensitivity C-reactive protein for patients
y is proportional to the statistical weight. The diamond indicates the
ents the 95% CI. CHF, chronic heart failure; hsCRP, high sensitivity C
l.
Figure 3 (See legend on next page.)
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Figure 3 Forest plots from meta-analysis of standardized mean difference in circulating tumor necrosis factor α (A), interleukin 1 (B)
and interleukin 6 (C) for patients with CHF randomized to fish oil or placebo. The effect size of each study is proportional to the statistical
weight. The diamond indicates the overall summary estimate for the analysis; the width of the diamond represents the 95% CI. CHF, chronic
heart failure; TNF-α, tumor necrosis factor α; IL-1, interleukin 1; IL-6, interleukin 6; SMD, standardized mean difference; CI, confidence interval.
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sVCAM-1
Only two studies [19,20] reported the effects of fish oil
supplementation on sICAM-1 and sVCAM-1 (Table 2).
For sICAM-1, estimation of the overall effects were per-
formed with random-effect model because significant
heterogeneity was found (I2 = 86.5%, p = 0.006); while
for sVCAM-1, fixed-effect model was applied because
no significant heterogeneity was found (I2 = 48.8%, p =
0.162). The pooled results indicated that additional sup-
plementation of fish oil didn’t affect the levels of circu-
lating sICAM-1 or sVCAM-1 (sICAM-1: SMD = -0.19,
95% CI -0.97 to 0.58, p = 0.63, Figure 4A; sVCAM-1:
SMD = -0.06, 95% CI -0.33 to 0.21, p = 0.65, Figure 4B).
Meta-regression and subgroup analysis was not per-
formed for these outcomes because of the limited num-
ber of studies included.
Publication bias
Publication bias was tested based on the data of TNF-α,
which included the most study arms. Funnel plot
(Figure 5) and Egger regression asymmetry test of the 7
included study arms suggested no significant publication
bias for TNF-α (Egger test, p = 0.372).
Discussion
In this meta-analysis, we summarized evidence from 7
published intervention trials that investigated the effects
of fish oil supplementation on circulating markers of in-
flammation in patients with CHF. The results showed
that fish oil reduced the circulating levels of TNF-α, IL-1
and IL-6 in patients with CHF, although the levels of
hsCRP, sICAM-1 and sVCAM-1 were not significantly
affected. Results of meta-regression and subgroup ana-
lysis suggested that supplementation with higher dose of
fish or for a longer follow-up duration might associate
with more remarkable reduction of TNF-α and IL-6
levels. These results suggested that anti-inflammation
may be a mechanism underlying the potential benefits of
fish oil for patients with CHF.
Results of a few epidemiologic studies demonstrated
that fish consumption or fish oil intake was inversely
associated with incidence of CHF in general population
[30-32]. Furthermore, recently published GISSI-HF trial
[9] showed that in patients with CHF on evidence-
based therapy, long term treatment with fish oil
reduced combined endpoint of mortality or hospitaliza-
tions for cardiovascular reasons. Besides, our recentlypublished meta-analysis also indicated that fish oil sup-
plementation can favorably affect the cardiac function
and functional capacity in CHF patients [33]. However,
the exact mechanisms of these beneficial effects of fish
oil to patients with CHF are not fully understood [15].
Accumulating evidence from animal experiments and
clinical investigations have revealed that CHF may at
least partially be an inflammatory disease, where various
cytokines and adhesion molecules are involved in CHF
pathogenesis and progression via contribution to endo-
thelial dysfunction, cardiomyocyte apoptosis, cardiac re-
modeling and left ventricular dysfunction [10,34-36].
These inflammatory markers, including hsCRP, TNF-α,
IL-1, IL-6, ICAM-1 and sVCAM-1 et al., were found to
be elevated in patients with CHF [37-42], and were
associated with the severity of the disease and the prog-
nosis of the patients [11-13]. Moreover, experimental
evidence suggested that inflammation may also be a
treatment target for CHF, and suppression of the above
inflammatory factors or inhibition their adverse bio-
logical effects in CHF may be of great potential thera-
peutic significance [14,36].
It has been suggested that fish oil supplementation may
exert anti-inflammation effects by decreasing the produc-
tion of inflammatory cytokines and adhesion molecules in
some of the inflammation associated diseases, such as
rheumatoid arthritis, inflammatory bowels diseases and
asthma, but there were also studies didn’t support this
concept [43,44]. Furthermore, a recent systematic review
in healthy subjects, subjects with cardiovascular risk and
established cardiovascular disease indicated that interven-
tion studies with fish oil in these population demon-
strated rather different results on inflammatory markers,
although the reasons for above controversy were un-
known [45]. Since anti-inflammation was suggested to be
involved in the therapeutic mechanisms of fish oil to car-
diovascular disorders, we systematically evaluated the
effects of additional fish oil supplementation on the circu-
lating levels of inflammatory markers in CHF patients.
The results of our meta-analysis indicated the suppressive
effects of fish oil on circulating TNF-α, IL-1 and IL-6,
suggesting the potential role of fish oil supplementation
in blunting the inflammatory response associated with
CHF and modifying the outcomes of these patients. Previ-
ous studies indicated that the potential mechanisms of fish
oil on these inflammatory markers may involve its ability
to modulation the nuclear transcription factor (NF-ΚB)
[46,47], which subsequently inhibited transcription of
Table 3 Subgroup estimation of the effects of fish oil supplementation on TNF-α and IL-6 in patients with CHF
TNF-α IL-6
Subgroup Study arms (n)/patients (n) SMD [95% CI] p※ Study arms (n)/patients (n) SMD (95% CI) p※
Age
≤ 60 years 3/57 -0.47 [-1.22, 0.27] 2/43 -0.80 [-1.45, -0.15]
> 60 years 4/285 -0.68 [-1.28, -0.08] 0.67 4/285 -0.81 [-1.72, 0.10] 0.99
Gender (male)
≤ 90% 4/244 -0.76 [-1.48, -0.03] 3/230 -1.02 [-1.77, -0.28]
> 90% 3/98 -0.44 [-0.87, -0.02] 0.46 3/98 -0.60 [-1.92, 0.72] 0.58
Ischemic CHF
Not excluded 3/125 -0.42 [-0.94, 0.09] 2/111 -0.05 [-1.17, 1.07]
Excluded 4/217 -0.71 [-1.34, -0.07] 0.50 4/217 -1.33 [-1.74, -0.92] 0.06
Baseline NYHA (class IV)
Not included 3/249 -0.85 [-1.51, -0.18] 3/249 -1.23 [-1.93, -0.54]
Included 3/57 -0.47 [-1.22, 0.27] 0.47 2/43 -0.80 [-1.45, -0.15] 0.37
Baseline LVEF
≤ 30% 3/57 -0.47 [-1.22, 0.27] 2/43 -0.80 [-1.45, -0.15]
> 30% 3/249 -0.85 [-1.51, -0.18] 0.47 3/249 -1.23 [-1.93, -0.54] 0.37
Baseline TNF-α
≤ 10 pg/ml 4/93 -0.33 [-0.82, 0.17] — —
> 10 pg/ml 3/249 -0.85 [-1.51, -0.18] 0.22 — — —
Baseline IL-6
≤ 5 pg/ml — — 3/79 -0.31 [-1.27, 0.65]
> 5 pg/ml — — — 3/249 -1.23 [-1.93, -0.54] 0.13
ACEI/ARB
Not all used 1/14 -1.41 [-2.62, -0.19] 0/0 —
All used 5/292 -0.62 [-1.17, -0.08] 0.25 5/292 -1.10 [-1.60, -0.60] —
β-blockers
Not all used 3/125 -0.42 [-0.94, 0.09] 2/111 -0.05 [-1.17, 1.07]
All used 4/217 -0.71 [-1.34, -0.07] 0.50 4/217 -1.33 [-1.74, -0.92] 0.06
EPA + DHA
≤ 1000 mg/d 3/133 -0.23 [-0.57, 0.11] 3/133 -0.26 [-1.06, 0.54]
> 1000 mg/d 4/209 -1.01 [-1.50, -0.53] 0.01 3/195 -1.47 [-1.84, -1.11] 0.007
EPA
≤ 800 mg/d 4/266 -0.51 [-1.20, 0.19] 4/266 -0.62 [-1.54, 0.29]
> 800 mg/d 3/76 -0.76 [-1.25, -0.27] 0.56 2/62 -1.25 [-1.93, -0.56] 0.28
DHA
≤ 1300 mg/d 4/266 -0.51 [-1.20, 0.19] 4/266 -0.62 [-1.54, 0.29]
> 1300 mg/d 3/76 -0.76 [-1.25, -0.27] 0.56 2/62 -1.25 [-1.93, -0.56] 0.28
EPA DHA ratio
≤ 1 3/210 -0.80 [-1.53, -0.07] 3/210 -0.88 [-2.20, 0.44]
> 1 4/132 -0.38 [-0.79, 0.03] 0.32 3/118 -0.66 [-1.04, -0.29] 0.76
Duration
≤ 4 months 5/168 -0.32 [-0.63, -0.01] 4/154 -0.38 [-1.02, 0.26]
> 4 months 2/174 -1.15 [-1.67, -0.62] 0.008 2/174 -1.59 [-1.93, -1.25] 0.001
Quality score
≤ 3 5/299 -0.77 [-1.32, -0.22] 4/285 -0.81 [-1.72, 0.10]
> 3 2/43 -0.16 [-0.78, 0.46] 0.15 2/43 -0.80 [-1.45, -0.15] 0.99
p※ difference between strata (Student’s t test).
TNF-α, tumor necrosis factor α; IL-6, interleukin 6; CHF, chronic heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor inhibitor; EPA, eicosapentaenoic acid; DHA, ducosahexenoic acid; SMD, standardized mean
difference; CI, confidence interval.
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Figure 4 Forest plots from meta-analysis of standardized mean difference in circulating soluble intracellular adhesion molecule-1 (A)
and soluble vascular cell adhesion molecule-1 (B) for patients with CHF randomized to fish oil or placebo. The effect size of each study is
proportional to the statistical weight. The diamond indicates the overall summary estimate for the analysis; the width of the diamond represents
the 95% CI. CHF, chronic heart failure; sICAM-1, soluble intracellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1;
SMD, standardized mean difference; CI, confidence interval.
Xin et al. BMC Cardiovascular Disorders 2012, 12:77 Page 9 of 11
http://www.biomedcentral.com/1471-2261/12/77above inflammatory markers in CHF. Besides, recent evi-
dence suggested that fish oil may transcriptionally up-
regulate adiponectin, a potential anti-inflammatory factor,
thereby suppressing above inflammatory cytokines [48,49].
Considering the significant heterogeneity that existed
in the pooled analysis of TNF-α and IL-6, we performed
meta-regression and predefined subgroup analysis toFigure 5 Funnel plot (with pseudo 95% CIs) of all individual
study arms in the meta-analysis of circulating TNF-α for
patients with CHF randomized to fish oil or placebo. CHF,
chronic heart failure; TNF-α, tumor necrosis factor α; SMD,
standardized mean difference; se, standard error; CI, confidence
interval.explore the potential sources. The results suggested that
the dose and follow-up duration of fish oil supplementa-
tion might influence the effects of fish oil on circulating
levels of TNF-α and IL-6 in patients with CHF, and a
higher dose of fish oil or a longer follow-up duration
seem to be associated with a more remarkable reduction
of circulating levels of TNF-α and IL-6. Notably, for the
studies included in meta-analysis of IL-1 [18,23], the
doses of fish oil are over 1000 mg/day and the follow-up
durations are 6 to 12 months, which made the pooled
result a reduction of IL-1 by fish oil supplementation.
High sensitivity C reactive protein is considered to be
of prognostic value in many cardiovascular diseases
[50,51], including CHF [13]. However, the pooled results
of our meta-analysis failed to demonstrate a significant
effect of fish oil supplementation on circulating level of
hsCRP in patients with CHF. These results are supposed
to be robust, because none of the included studies in
meta-analysis of hsCRP showed a significant influence of
fish oil supplementation on circulating hsCRP levels,
and the heterogeneity among these studies was very lit-
tle. The nonsignificant efficacy of fish oil supplementa-
tion on circulating hsCRP levels in the included CHF
patients of this meta-analysis may be explained by the
following two reasons. First, the patients of the included
studies were in stable clinical and hemodynamical condi-
tions receiving treatment of the optimal medications
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http://www.biomedcentral.com/1471-2261/12/77(including neurohormonal inhibitors in all studies and
statins in some studies) according to the current guide-
lines. Therefore, the mean baseline circulating levels of
hsCRP for the participants of included studies were rela-
tively low (1.3 to 5.6 μg/ml, Table 2) and additional sup-
plementation of fish oil had little effect on it. Second,
the low number of included studies (4 studies) and the
small size of the included population (285 patients) may
make the analysis underpowered to show significant
effect.
Our meta-analysis also failed to show a significant effi-
cacy of fish oil supplementation on the levels of sICAM-
1 and sVCAM-1 in CHF. These results, from our point
of view, may also be attributed to the low number of
included studies (2 studies) and the small size of the
included population (213 patients).
Several potential limitations should be addressed
regarding the present meta-analysis. First, the numbers
of studies and patients included in this meta-analysis
were small, so results of some of estimations, such as for
the effects of fish oil supplementation on IL-1, sICAM-1
and sVCAM-1, should be interpreted with caution. Sec-
ond, because baseline data of statins using in half of the
included study arms were unavailable, we were unable to
estimate the effects of statins using on the pooled ana-
lysis of the inflammatory markers. This may be an im-
portant source of heterogeneity. Third, as for the
subgroup analysis, the number of included studies and
patients in each stratum is relatively small. Besides, we
did not have access to individual patient data. Some sub-
group analysis of CHF patients might show a difference
with fish oil supplementation if larger numbers of
patients were included or individual patient data were
available (e.g. fish oil supplementation on circulating IL-
6 in ischemic and non-ischemic CHF patients). Fourth,
this meta-analysis included one study [21,22] in which
the data were imputed from median and IQRs for some
outcomes. Although inclusion of the imputed data may
add to the potential bias, sensitivity analysis by excluding
this study showed generally consistent results with
which all the studies were included. Furthermore, we
considered this as the best possible approach to not ex-
clude valuable data from related studies.
Conclusion
In conclusion, our meta-analysis, by pooling the limited
trials available currently, indicates that additional supple-
mentation of fish oil may reduce the circulating levels of
TNF-α, IL-1 and IL-6 in patients with CHF, although the
levels of hsCRP, sICAM-1 and sVCAM-1 were not sig-
nificantly affected. Also, greater reduction of TNF-α and
IL-6 might be seen in patients who take fish oil in a
higher dose or for a longer duration. These results sug-
gested that anti-inflammation might be a possiblemechanism underlying the potential beneficial effects of
fish oil supplementation to patients with CHF. Addition-
ally, large-scale randomized controlled trials with ad-
equate power are warranted in the future to confirm
these effects.
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